Introduction: Atopic dermatitis is a relapsing, chronic, inflammatory dermatosis. So far, treatment options for more severe forms of the disease have been limited. The prospect has changed with the advent of biological drug registrations. Dupilumab is a monoclonal antibody target...
2024. The abstract was titled ‘Integrated safety of dupilumab up to 5 years for the treatment of moderate‑to‑severe atopic dermatitis in infants, children, adolescents, and adults,’ and it was authored in part by Richard Langley, MD,...
[5] Marlene Seegräber, et al. Expert Rev Clin Pharmacol. Dupilumab for treatment of atopic dermatitis AbMole奥默
"Dupilumab has proven to be an important treatment forpediatric patientssuffering from atopic dermatitis. Our recent research was to help us know if the drug would be as effective in patients with both atopic dermatitis and other common atopic diseases that could add to the inflammatory burden," ...
Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real-world evidence is still scarce. Thirty-nine pediatric patients with uncontrolled AD who regularly recei...
Reactions to the efficacy and safety of dupilumab treatment for atopic dermatitis as demonstrated by clinical trial data and real-world experience. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CLOUD_ERR_UNKNOWN Technical details : Unknown ...
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. PMID: 35703018 Dupilumab for treatment of atopic dermatitis. PMID: 29557246 Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review. PMID: 37100035 ...
Dupilumab for treatment of atopic dermatitis. PMID: 29557246 Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review. PMID: 37100035 Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians. PMID: 34855151 ...
Dupilumab for the treatment of atopic dermatitis: A clinical trial review Introduction: Current treatment options for moderate-to-severe atopic dermatitis (AD) are limited and have potentially dangerous side effects. Dupilumab is... S Mcgregor,ME Farhangian,SR Feldman - 《Expert Opinion on ...
Atopic dermatitis (AD) is a chronic pruritic skin disease that can have a profound negative impact on patients’ quality of life, especially in cases of inadequate disease control. Dupilumab, a dual inhibitor of IL-4 and IL-13 signaling, is approved in the United States for the treatment of...